Alessia Cavo

8PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 22, 2026
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

|Aug 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

Alessandra Damassi, Malvina Cremante, Alessio Signori

|Jan 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).

Marco Stellato, Sebastiano Buti, Marco Maruzzo

|May 27, 2022
Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy.

Manlio Mencoboni, Vincenzo Fontana, Azzurra Damiani

|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna

|Apr 03, 2021
Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis.

Manlio Mencoboni, Marcello Ceppi, Marco Bruzzone

Pageof 2

Frequent Collaborators

3 joint publications

Sara Elena Rebuzzi

3 joint publications

Sebastiano Buti

2 joint publications

Rosa Angela Filiberti

2 joint publications

Giuseppe Luigi Banna